Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Oruka Therapeutics Initiates Dosing Of Healthy Volunteers In Its First Clinical Trial Of ORKA-002, The Company's Novel, Subcutaneously Administered, Half-life Extended Monoclonal Antibody Targeting IL-17A And IL-17F

Author: Benzinga Newsdesk | May 20, 2025 03:04pm

Posted In: ORKA